Лираглутид – первый аналог человеческого глюкагоноподобного пептида-1 для введения один раз в сутки: новый этап в терапии сахарного диабета типа 2
Лираглутид – первый аналог человеческого глюкагоноподобного пептида-1 для введения один раз в сутки: новый этап в терапии сахарного диабета типа 2
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Список литературы
1. Дедов И.И. Новые возможности терапии сахарного диабета 2 типа. Сахарный диабет. Новые возможности терапии сахарного диабета 2 типа. Спец. вып. 2009, 1–3.
2. Дедов И.И., Шестакова М.В. Комментарии ведущих специалистов к ст.: «Влияние лираглутида на биомаркеры сердечно-сосудистого риска у больных СД 2 типа». Болезни сердца и сосудов. 2009; 4 (2).
3. Buse J et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
4. Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373 (9662): 473–81.
5. Garber A, Henry R et al. Monotherapy with Liraglutide, a Once-Daily Human GLP-1 Analog, Provides Sustained Reductions in A1C, FPG, and Weight Compared with Glimepiride in Type 2 Diabetes: LEAD-3 mono 2-year. Results Diabetes 2009; 58 (Suppl. 1): A42 (abstract 162-OR).
6. Garber A. Glucagon-like peptide-1 – based therapies: new developments and emerging data. J Diab Obesity Metab 2008; 10 (Suppl. 3): 22–35.
7. Mari A, Degn K, Brock B et al. Characterisation of beta-cell function improvement by liraglutide: modelling analysis of 24-h tests. Diabetes 2006; 55 (Suppl. 1): A124 (Abstract 522-P).
8. Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009; 268–78.
9. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340–8.
10. Nauck M et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 84–90.
11. Nauck M, Pratley R et al. Adding Liraglutide to Existing Therapy rather.
12. Nauck M, Stoöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52.
13. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87 (3): 1239–46.
14. Nauk MA, Marre M. Adding Liraglutide to oral antidiabetic drug monotherapy: Efficacy and Weight Benefits. Postgraduate Medicine 2009; 121 (3).
15. Pratley et al. Liraglutide compared to sitagliptin, both in combination with metformin, in subjects with type 2 diabetes: a 26-week, randomised, parallel-group, open-label trial Lancet 2010; 375: 1447–56.
16. Russell-Jones D et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009. In press.
17. Than Substituting it for Existing Therapy Produces Greater Improvement in Glycemic Control: Evidence from a Meta-analysis. 69th ADA Scientific Sessions Abstract Book, Poster 549, 2009.
18. Vilsboll T, Brock B, Perrild H et al. Liraglutide, a oncedaily human GLP-1 analogue improves beta-cell function and arginine stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008; 25: 152–6.
19. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes 2006; 55 (Suppl. 1): Abstract 2007-PO.
20. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care2007; 30: 1608–10.
21. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007; 16: 231–7.
22. Zinman B et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. Published online March 16, 2009 (DOI:10.2337/dc08–2124).
23. Zinman B, Buse J et al. Liraglutide more effectively achieves a composite endpoint for HbA1c, SBP and weight change than other diabetes therapies Liraglutide meta-analyses 69th ADA Scientific Sessions Abstract Book, Poster 537, 2009.
24. Zinman et al. Diabetologia 2009; 52 (Suppl. 1): S291 (Abstr. 743).
2. Дедов И.И., Шестакова М.В. Комментарии ведущих специалистов к ст.: «Влияние лираглутида на биомаркеры сердечно-сосудистого риска у больных СД 2 типа». Болезни сердца и сосудов. 2009; 4 (2).
3. Buse J et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
4. Garber A et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373 (9662): 473–81.
5. Garber A, Henry R et al. Monotherapy with Liraglutide, a Once-Daily Human GLP-1 Analog, Provides Sustained Reductions in A1C, FPG, and Weight Compared with Glimepiride in Type 2 Diabetes: LEAD-3 mono 2-year. Results Diabetes 2009; 58 (Suppl. 1): A42 (abstract 162-OR).
6. Garber A. Glucagon-like peptide-1 – based therapies: new developments and emerging data. J Diab Obesity Metab 2008; 10 (Suppl. 3): 22–35.
7. Mari A, Degn K, Brock B et al. Characterisation of beta-cell function improvement by liraglutide: modelling analysis of 24-h tests. Diabetes 2006; 55 (Suppl. 1): A124 (Abstract 522-P).
8. Marre M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabetic Medicine 2009; 268–78.
9. Muscelli E, Mari A, Casolaro A et al. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients. Diabetes 2008; 57: 1340–8.
10. Nauck M et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009; 32: 84–90.
11. Nauck M, Pratley R et al. Adding Liraglutide to Existing Therapy rather.
12. Nauck M, Stoöckmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 1986; 29: 46–52.
13. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 2002; 87 (3): 1239–46.
14. Nauk MA, Marre M. Adding Liraglutide to oral antidiabetic drug monotherapy: Efficacy and Weight Benefits. Postgraduate Medicine 2009; 121 (3).
15. Pratley et al. Liraglutide compared to sitagliptin, both in combination with metformin, in subjects with type 2 diabetes: a 26-week, randomised, parallel-group, open-label trial Lancet 2010; 375: 1447–56.
16. Russell-Jones D et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU). Diabetologia 2009. In press.
17. Than Substituting it for Existing Therapy Produces Greater Improvement in Glycemic Control: Evidence from a Meta-analysis. 69th ADA Scientific Sessions Abstract Book, Poster 549, 2009.
18. Vilsboll T, Brock B, Perrild H et al. Liraglutide, a oncedaily human GLP-1 analogue improves beta-cell function and arginine stimulated insulin secretion at hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med 2008; 25: 152–6.
19. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide treatment, blood pressure and biomarkers of cardiovascular risk in patients with type 2 diabetes: 14 weeks monotherapy study. Diabetes 2006; 55 (Suppl. 1): Abstract 2007-PO.
20. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human GLP-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes mellitus. Diabetes Care2007; 30: 1608–10.
21. Vilsboll T. Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2007; 16: 231–7.
22. Zinman B et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care. Published online March 16, 2009 (DOI:10.2337/dc08–2124).
23. Zinman B, Buse J et al. Liraglutide more effectively achieves a composite endpoint for HbA1c, SBP and weight change than other diabetes therapies Liraglutide meta-analyses 69th ADA Scientific Sessions Abstract Book, Poster 537, 2009.
24. Zinman et al. Diabetologia 2009; 52 (Suppl. 1): S291 (Abstr. 743).
Авторы
М.В.Шестакова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.